takeda_world

Takeda partners with Zydus to develop chikungunya vaccine

pharmafile | September 20, 2016 | News story | Manufacturing and Production, Research and Development Takeda, Zydus Cadila, chikungunya 

Zydus Cadila has teamed up with Takeda to develop a vaccine for the chikungunya virus.

Zydus Cadila’s group firm Cadila Healthcare said in a BSE filing: “The broad-based agreement includes early stage development to the final commercialisation of the vaccine. There is currently no vaccine to prevent or medicine to treat chikungunya virus infection,”

Chikungunya is a mosquito-borne viral disease that causes fever and severe joint pain and has seen sporadic outbreaks across Asia, Europe and the Americas. The Japanese pharma giant will partner with the Indian firm to develop the first preventative measure for the illness.

 “By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all-important step to prevent the disease burden,” commented Zydus group chairman and MD, Pankaj R Patel.

Takeda Vaccines COO Rahul Singhvi added: “Takeda is the centre of important vaccine-related activities in global health and emerging infectious diseases. This is another demonstration of Takeda’s major commitment to the health of children in developing countries and elsewhere around the world.”

Matt Fellows

Related Content

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which …

Latest content